Heike Keilhack, Ph.D.
Senior Vice President of Biological Sciences
Dr. Keilhack is an accomplished cancer biologist with rich experience in cell biology, animal models of cancer, pharmacology and translational medicine with over 14 years of experience in oncology drug discovery in both small biotechnology companies and large pharmaceutical companies. Prior to joining Ribon, Dr. Keilhack was Senior Director of Biology at Epizyme where, among other responsibilities, she was the project leader for the company’s EZH2 inhibitor program, currently in late-stage clinical testing. Before that, she was a research fellow at Merck and the biology project lead for the company’s clinical stage AKT inhibitor, MK-2206.
Dr. Keilhack received her Ph.D. in Biochemistry at Friedrich Schiller University of Jena (Germany) and completed postdoctoral training at the Harvard Medical School. She earned a B.S. in Biochemistry at Martin Luther University of Halle-Wittenberg (Germany).